Share price estimates for Sanofi
Headquartered in Paris, Sanofi (SNY) is a leading global pharmaceutical company. It operates in the Pharmaceuticals, Human Vaccines, and Animal Health segments. Pharmaceuticals contributed ~80% to the company’s total revenues, whereas the Vaccines segment’s share was ~12.8% in 2015.
The above table demonstrates two brokerage firms and their estimated target price for Sanofi. The consensus 12-month target price for Sanofi is $52. This translates to an ~31.3% return compared to Sanofi’s closing price of $39.60 on March 3, 2016.
According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.” None of the brokerage firms issued a “sell” rating on the stock.
Analyst recommendations for peers
According to the Bloomberg survey of 26 analysts on March 3, 2016, 69.2% of the analysts issued a “buy” rating for Eli Lilly (LLY), whereas 30.8% suggested that the stock is a “hold.” None of the analysts recommended a “sell” rating for Eli Lilly.
Following 23 analysts’ rating from Bloomberg consensus dated March 3, 2016, 43.5% believed Merck & Co.(MRK) should be a “buy,” whereas 56.5% recommended a “hold” rating for the company. None of the analysts rated the stock as a “sell.”
Bloomberg’s consensus of six analysts as of March 3, 2016, indicated that 14.3% of the analysts issued a “buy” rating for AstraZeneca (AZN), whereas 71.4% recommended the stock as a “hold.” The remaining 14.3% of analysts suggested that the stock should be a “sell.”
The following articles will cover the valuation catalysts for Sanofi. The expectations of the financial communities can help investors gain insight into the company and understand the rationales behind such estimates.
Investors who prefer not to take direct exposure to individual stocks can look for options such as the First Trust Value Line Dividend Index ETF (FVD). FVD holds 0.48% of its total holdings in Sanofi stock.